{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-028487","form_type":"8-K","ticker":"CLSDQ","cik":"0001539029","company_name":"Clearside Biomedical, Inc.","filed_at":"2024-02-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.552833+00:00","generated_at":"2026-06-06T05:37:21.832774+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Clearside Biomedical prices $15M registered direct offering of 11.1M shares and warrants","bullets":["Gross proceeds ~$15M from sale of 11,111,111 shares and warrants at $1.35 per unit.","Warrants exercisable at $1.62/share for 5 years from August 2024.","Offering expected to close February 9, 2024 with Citizens JMP Securities as placement agent.","Net proceeds for working capital; management says cash runway extends into Q3 2025.","Placement agent fee of 6.0% of gross proceeds plus reimbursement of expenses."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-028487","json":"https://secwatch.observer/filing/0001193125-24-028487.json","markdown":"https://secwatch.observer/filing/0001193125-24-028487.md","text":"https://secwatch.observer/filing/0001193125-24-028487.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1539029/000119312524028487/0001193125-24-028487-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1539029/000119312524028487/d754271d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T05:37:21.832774+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1f58cf89e9970a07f18910169a55a80ab29092c8","claim":"Clearside Biomedical, Inc. entered into Purchase Agreement with institutional investors and an existing stockholder valued at approximately $15.0 million (effective 2024-02-06).","evidence_excerpt":"On February 6, 2024, Clearside Biomedical, Inc. (“Clearside” or the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with institutional investors and an existing stockholder, pursuant to which the Company agreed to issue and sell, in a registered direct offering (the “Registered Direct Offering”): (i) an aggregate of 11,111,111 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share; and (ii) warrants to purchase up to 11,111,111 shares of Common Stock (the “Warrants”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1539029/000119312524028487/0001193125-24-028487-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"institutional investors and an existing stockholder"},{"label":"Value","value":"approximately $15.0 million"},{"label":"Effective","value":"2024-02-06"}],"fact_type":"material_agreement"},{"claim_id":"bbb4328df4f9070eb1ebaf886faee47c42e60e91","claim":"Clearside Biomedical, Inc. entered into Placement Agency Agreement with Citizens JMP Securities, LLC (effective 2024-02-06).","evidence_excerpt":"Citizens JMP Securities, LLC acted as the placement agent (the “Placement Agent”) in connection with the Registered Direct Offering pursuant to the Placement Agency Agreement, dated February 6, 2024 (the “Placement Agency Agreement”), by and between the Company and the Placement Agent.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1539029/000119312524028487/0001193125-24-028487-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Citizens JMP Securities, LLC"},{"label":"Effective","value":"2024-02-06"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}